Neuropsychopharmacology Reports最新文献

{"title":"Association Between Psychiatrists' Subjective Clinical Behavior Scores and Objective Quality Indicators Based on Discharge Prescriptions: A Nationwide Multicenter Study Based on the EGUIDE Project.","authors":"Kazuhiko Yamamuro, Naomi Hasegawa, Yusuke Arai, Hikaru Hori, Hiroyuki Muraoka, Toru Horinouchi, Naoki Hashimoto, Shinichiro Ochi, Takashi Tsuboi, Hirotaka Yamagata, Junya Matsumoto, Satsuki Ito, Toshiaki Onitsuka, Kazutaka Ohi, Hisashi Yamada, Jun-Ichi Iga, Ken Inada, Koichiro Watanabe, Norio Yasui-Furukori, Ryota Hashimoto","doi":"10.1002/npr2.70110","DOIUrl":"10.1002/npr2.70110","url":null,"abstract":"<p><strong>Aim: </strong>Psychiatrists often perceive their clinical practices as guideline-concordant; however, discrepancies frequently exist between perceived and actual prescribing behaviors. To explore this gap, we examined the association between self-assessed clinical behavior scores (CBs) and prescribing practices objectively evaluated using quality indicators (QIs) within the EGUIDE educational program framework for schizophrenia and major depressive disorder. Identifying such associations is essential for improving care quality and developing interventions fostering evidence-based practice.</p><p><strong>Methods: </strong>A prospective observational multicenter study was conducted across Japan involving 820 psychiatrists from university, public, and private hospitals participating in EGUIDE, along with patients diagnosed with schizophrenia (n = 6714) or major depressive disorder (n = 3692) treated at these institutions. The outcome measures were associations between psychiatrists' CB scores and quality indicators (QIs) based on discharge prescriptions; these were analyzed using logistic regression adjusted for age, sex, and institution type.</p><p><strong>Results: </strong>For schizophrenia, CBs were significantly associated with 8 of 11 QIs, including treatment-resistant assessment, antipsychotic monotherapy (with/without other psychotropics), absence of anxiolytics/hypnotics, mood stabilizers, anticholinergics, PRN psychotropics, and clozapine use. For major depressive disorder, 3 of 7 QIs showed significant associations: severity assessment, no anxiolytic/hypnotic prescriptions, and use of modified electroconvulsive therapy.</p><p><strong>Conclusion: </strong>Self-assessed clinical behavior scores partially reflect actual prescribing practices. These findings highlight the value of incorporating subjective evaluations into clinical performance assessment tools to promote guideline adherence. Moreover, our results suggest that collecting self-assessments may offer a feasible and scalable strategy for identifying areas where additional education or system-level support is needed to enhance evidence-based prescribing in diverse clinical settings.</p><p><strong>Trial registration: </strong>University Hospital Medical Information Network registry identifier: UMIN000022645.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"46 2","pages":"e70110"},"PeriodicalIF":1.9,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13581080/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147513566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to \"Probiotic Supplementation and Executive Function in Children With Attention-Deficit/Hyperactivity Disorder\".","authors":"","doi":"10.1002/npr2.70130","DOIUrl":"10.1002/npr2.70130","url":null,"abstract":"","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"46 2","pages":"e70130"},"PeriodicalIF":1.9,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13239969/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148016523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Electroconvulsive Therapy for Severe Refractory Tardive Dystonia Without Active Depression: A Case Report.","authors":"Tomohiro Asahi, Yasushi Kawamata, Norio Sugawara, Ryo Maehara, Norio Yasui-Furukori","doi":"10.1002/npr2.70128","DOIUrl":"10.1002/npr2.70128","url":null,"abstract":"<p><strong>Background: </strong>Tardive dystonia is a disabling tardive syndrome associated with exposure to dopamine receptor-blocking agents. Responses to pharmacotherapy are often limited, and evidence supporting electroconvulsive therapy (ECT) remains sparse.</p><p><strong>Case presentation: </strong>A woman in her early 60s with recurrent major depressive disorder (in full remission at presentation) developed progressive cervical-truncal dystonia with tremor-like involuntary movements after years of fluctuating psychotropic regimens that included exposure to antipsychotic medication. Neurologic evaluation, including brain magnetic resonance imaging and electroencephalography, was unremarkable, and no structural, metabolic, or neurodegenerative cause was identified from available records. Multiple pharmacologic strategies-including anticholinergics, benzodiazepines, and valbenazine-provided insufficient control, and she became wheelchair-dependent. During a recent psychiatric admission, she received ECT primarily for refractory tardive dystonia. Severity was tracked using the Abnormal Involuntary Movement Scale (AIMS), which was 27 at admission and 25 immediately before ECT. After benzodiazepines were discontinued, she underwent an acute course of bitemporal ECT over approximately 6 weeks under propofol (50 mg) and succinylcholine (50 mg) anesthesia, with a recorded stimulus charge of 100 mC and pulse width of 1.0 ms. Seizure duration on electroencephalography ranged from 25 to 85 s (motor 25-59 s when recorded), and the device/local-record postictal suppression index was 1-2. Motor symptoms improved progressively; by the middle of the course, she no longer required a wheelchair and ambulated independently. The AIMS score decreased to 14 later in the course and remained 14 at completion of the acute course. However, dystonia gradually recurred after ECT discontinuation.</p><p><strong>Conclusion: </strong>ECT may provide clinically meaningful short-term improvement in severe refractory tardive dystonia even in the absence of active depressive symptoms; relapse after acute treatment may occur, and continuation strategies may be required.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"46 2","pages":"e70128"},"PeriodicalIF":1.9,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13184171/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147974061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Distinct Effects of Nonselective Rho-Kinase Inhibitor Fasudil and Selective Rho-Kinase 2 Inhibitor KD025 on Serotonin and Dopamine Release in the Nucleus Accumbens of Mice.","authors":"Rinako Tanaka, Wenjun Zhu, Taku Nagai, Toshitaka Nabeshima, Kozo Kaibuchi, Norio Ozaki, Hiroaki Ikesue, Hiroyuki Mizoguchi, Kiyofumi Yamada","doi":"10.1002/npr2.70124","DOIUrl":"10.1002/npr2.70124","url":null,"abstract":"<p><p>Recent studies have indicated that the Rho GTPase family and Rho-kinases are associated with psychiatric diseases, such as schizophrenia. Two subtypes of Rho-kinase, Rho-kinases 1 and 2, regulate actin dynamics and mediate neurite outgrowth, spine morphology in neurons, and neurotransmitter release in vitro and ex vivo. However, the precise role of Rho-kinases in neurotransmitter release in vivo remains unclear. To clarify the role of Rho-kinases 1 and 2 in serotonin and dopamine release in the nucleus accumbens (NAc) of mice in vivo, we investigated the effect of a nonselective Rho-kinase inhibitor, fasudil, and a selective Rho-kinase 2 inhibitor, KD025, using an in vivo microdialysis technique. Fasudil perfusion (1-20 μM) into the NAc increased the basal extracellular serotonin level but did not affect dopamine levels, whereas KD025 (10-20 μM) had little effect on basal serotonin and dopamine levels. Notably, fasudil perfusion into the NAc suppressed depolarization-induced serotonin and dopamine release in a dose-dependent manner, whereas KD025 selectively suppressed depolarization-induced serotonin release. Our results suggested that Rho-kinases 1 and 2 are associated with dopamine and serotonin release, respectively, and that both may have significant but distinct roles in the regulation of serotonin and dopamine release in the NAc.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"46 2","pages":"e70124"},"PeriodicalIF":1.9,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13112600/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147776405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adolescent Exposure to Nicotine and Ethanol Attenuates Adult Nicotine Reward Sensitivity in Rats.","authors":"Michimasa Toyoshima, Ryota Toyofuku, Shota Shimoda, Lena Tsuchida, Reina Tachihara, Kazuo Yamada","doi":"10.1002/npr2.70132","DOIUrl":"10.1002/npr2.70132","url":null,"abstract":"<p><p>Adolescence is a sensitive developmental stage in which exposure to addictive substances can produce long-lasting changes in the neural circuits that regulate reward. Nicotine and ethanol are frequently co-used among adolescents, and converging evidence suggests that these drugs interact to modulate mesolimbic dopamine transmission. The present study investigated how chronic exposure to nicotine, ethanol, or their combination during adolescence influences adult conditioned place preference (CPP) for nicotine. Male Wistar-Imamichi rats were assigned to four groups: Control (no drug exposure), Nicotine (0.20 mg/kg/day, s.c., PND 28-41), EtOH (voluntary 20% ethanol intake), and Co-use (nicotine + ethanol). After maturation, all animals underwent CPP with 0.08 mg/kg nicotine using an unbiased procedure. We hypothesized that adolescent drug exposure would enhance vulnerability to nicotine reward in adulthood. Contrary to this hypothesis, only the Control group exhibited significant CPP, whereas no nicotine-induced preference was observed in any drug-exposed group. These findings emphasize the complexity of developmental drug interactions and suggest that adolescent exposure to addictive substances does not uniformly increase vulnerability to nicotine reward.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"46 2","pages":"e70132"},"PeriodicalIF":1.9,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13240331/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147974034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RETRACTION: Assessment of Cognitive-Motor Functions in Adults With Perceived Neuropsychological Problems Using NIH Toolbox After Remote Biofield Energy Treatment as Non-Pharmacological Intervention: A Randomized Double-Blind Placebo Controlled Trial.","authors":"","doi":"10.1002/npr2.70098","DOIUrl":"10.1002/npr2.70098","url":null,"abstract":"<p><strong>Retraction: </strong>M. K. Trivedi, A. Branton, D. Trivedi, S. Mondal and S. Jana, \"Assessment of Cognitive-Motor Functions in Adults With Perceived Neuropsychological Problems Using NIH Toolbox After Remote Biofield Energy Treatment as Non-Pharmacological Intervention: A Randomized Double-Blind Placebo Controlled Trial,\" Neuropsychopharmacology Reports 44, no. 4 (2024): 749-761, https://doi.org/10.1002/npr2.12482. The above article, published online on 13 September 2024 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal Editor-in-Chief, Tsuyoshi Miyakawa; the Japanese Society of Neuropsychopharmacology; and John Wiley & Sons Australia, Ltd. The retraction has been agreed upon as the study's design, methods, results and conclusions are essentially the same as another article published elsewhere by the same author group in the same year, without any attribution to that article. Furthermore, the study contains physiologically implausible data and statistical anomalies. The editors consider the results and conclusions of this article to be invalid. The authors do not agree with the retraction.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"46 1","pages":"e70098"},"PeriodicalIF":1.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12912925/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146213658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Persistent Interleukin-1β Elevation in Post-COVID-19 Patients: Findings From a Nationwide Registry Study in Japan.","authors":"Naoki Takamatsu, Hiroki Kimura, Mari S Oba, Hiroyuki Chiba, Ikue Umemoto, Yuki Moriyama, Nobuaki Matsunaga, Shinichiro Morioka, Daisuke Mori, Kazuhiro Hara, Aya Ogura, Kazufumi Yoshida, Hirohisa Watanabe, Satoshi Maesawa, Masashi Ikeda, Masahisa Katsuno, Norio Ohmagari, Masaki Takao, Shinsuke Kito, Norio Ozaki, Hironori Kuga","doi":"10.1002/npr2.70082","DOIUrl":"10.1002/npr2.70082","url":null,"abstract":"<p><strong>Aim: </strong>COVID-19 has been associated with dysregulated immune responses, with increasing evidence indicating sustained inflammasome activation and subsequent pro-inflammatory cytokine production. This study aimed to characterize the temporal profile of inflammatory markers, particularly interleukin (IL)-1β, in post-COVID-19 patients compared with pre-pandemic healthy controls, using data from the Psychiatric Symptoms for COVID-19 Registry Japan (PSCORE-J).</p><p><strong>Methods: </strong>Blood samples were analyzed from 119 post-COVID-19 patients (median age 45 years) recruited during 2023 and 374 pre-pandemic healthy controls (median age 65 years). For post-COVID-19 patients, samples were collected at baseline, 3 months, and 9 months. Multiple inflammatory markers were assessed, including IL-1β, IL-6, IL-8, IL-10, IL-12, TNF-α, IFN-γ, IFN-β, IP-10, ACE2, and eotaxin. Age- and sex-adjusted analyses were performed on log-transformed IL-1β levels.</p><p><strong>Results: </strong>IL-1β levels were significantly elevated in post-COVID-19 patients compared with healthy controls across all age groups (under 30s: 0.69 ± 0.33 vs. 0.25 ± 0.03; 30s: 0.70 ± 0.63 vs. 0.26 ± 0.09; 40s: 0.84 ± 0.76 vs. 0.30 ± 0.23; 50s: 0.67 ± 0.65 vs. 0.26 ± 0.10; 60 or over: 0.54 ± 0.30 vs. 0.26 ± 0.23 pg/mL). This elevation was sustained throughout the 9-month follow-up (baseline: 0.500 [0.33-0.890]; 3 months: 0.630 [0.28-1.290]; 9 months: 0.54 [0.29-0.96] pg/mL) compared with controls (0.24 [0.21-0.27] pg/mL). Other inflammatory markers showed either no significant differences or were paradoxically lower in patients.</p><p><strong>Conclusion: </strong>SARS-CoV-2 infection is associated with persistent elevation of IL-1β levels that remains stable over a 9-month period, suggesting sustained inflammasome activation. These findings provide novel insight into post-COVID-19 inflammatory processes and may have important implications for understanding both acute and chronic manifestations of the disease.</p><p><strong>Trial registration: </strong>Japan Registry of Clinical Trials: jRCT1030220711.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"46 1","pages":"e70082"},"PeriodicalIF":1.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12949360/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147317918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synergistic Effect of Combination Treatment of Brexpiprazole and Nalmefene on Ethanol Intake in Rats.","authors":"Naoki Amada, Mai Nakamura, Yuta Ohgi, Yusuke Kakumoto, Mikio Suzuki, Takashi Futamura, Kenji Maeda","doi":"10.1002/npr2.70107","DOIUrl":"10.1002/npr2.70107","url":null,"abstract":"<p><strong>Aims: </strong>Reduction of alcohol consumption is one of treatment goals to reduce harm among individuals with alcohol use disorder (AUD), a major worldwide health problem, for which nalmefene, an opioid receptor modulator, is used. In this study, the effect of nalmefene on ethanol (EtOH) intake, already reported, was evaluated in Wistar rats, as validation. In addition, effects of brexpiprazole, serotonin-dopamine activity modulator, alone and in combination with nalmefene were evaluated to investigate further treatment option for AUD.</p><p><strong>Methods: </strong>During the first training phase, animals had 10% EtOH as the only drinking fluid available for the first 5 days. Then, the animals had a 24-h free choice between EtOH and water for 39 days which is named the continual access paradigm. Thereafter, the limited access paradigm, which restricted the availability of 10% EtOH to 1 h every day, was carried out for 114 days. EtOH intake (g/kg/1 h) was determined by weighing 10% EtOH bottles before and after the limited EtOH access every day. Brexpiprazole (0.01-0.1 mg/kg, orally) and nalmefene (0.04-0.4 mg/kg, subcutaneously) were daily administered to rats 1 h or 20 min before starting the limited access paradigm for consecutive 4 days, respectively. The combination effect was evaluated using each subeffective dose of brexpiprazole and nalmefene which did not significantly reduce EtOH intake. The daily and the average EtOH intake for 4 days before and during the treatment with test compounds were statistically analyzed.</p><p><strong>Results: </strong>Brexpiprazole (0.1 mg/kg) and nalmefene (0.4 mg/kg) alone significantly decreased EtOH intake. Moreover, the combination of subeffective doses of brexpiprazole (0.01 mg/kg) and nalmefene (0.04 mg/kg) significantly and synergistically decreased EtOH intake.</p><p><strong>Conclusion: </strong>These data suggest that brexpiprazole may have the potential to decrease alcohol intake in AUD patients. In addition, brexpiprazole may have a synergistic therapeutic effect with nalmefene in those patients.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"46 1","pages":"e70107"},"PeriodicalIF":1.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12966623/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147369920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Probiotic Supplementation and Executive Function in Children With Attention-Deficit/Hyperactivity Disorder.","authors":"Abdolrahman Parhiz, Pegah Samani, Majid Kamali, Yeganeh Shekari, Niayesh Naghshi, Newsha Faghihshojaei, Faezeh Tejareh, Niloufar Pourmalek Lahiji, Ali Nori, Atefeh Aminifard, Parsa Bahmani, Saeid Doaei, Fatemeh Rabipour, Maryam Gholamalizadeh","doi":"10.1002/npr2.70084","DOIUrl":"10.1002/npr2.70084","url":null,"abstract":"<p><strong>Background: </strong>Attention Deficit Hyperactivity Disorder (ADHD) is a prevalent neurodevelopmental condition marked by inattention, hyperactivity, and impulsivity, which substantially impacts children's academic and social performance. The aim of this research was to examine the effect of probiotic supplementation on executive functioning in children with ADHD.</p><p><strong>Methods: </strong>This triple-blind, randomized controlled trial included 84 children with ADHD who were randomly allocated to receive either a probiotic supplement including Lactobacillus Acidophilus, Bifidobacterium Lactis, and Bifidobacterium Longum or a placebo, administered once daily for 2 months. Executive function was assessed using the parent form of the Behavior Rating Inventory of Executive Function (BRIEF) questionnaire. The data were analyzed using repeated measures analysis of variance after adjusting the confounding variables.</p><p><strong>Results: </strong>No significant difference was found between executive function scores of the groups at baseline (191.45 ± 20.725 vs. 190.55 ± 23.520, p = 0.214). Probiotic treatment significantly improved the scores of the intervention group compared to the control group (151.50 ± 16.784 vs. 190.68 ± 23.479, F = 7.93, p < 0.001) after adjusting for the confounders including age, BMI, and IQ.</p><p><strong>Conclusion: </strong>Probiotics may be beneficial as non-pharmacological adjunctive therapy for enhancing executive function in children with ADHD. Further studies with extended follow-up durations and objective neuropsychological evaluations are warranted.</p><p><strong>Trial registration: </strong>IRCT: IRCT20210531051454N2.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"46 1","pages":"e70084"},"PeriodicalIF":2.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12741551/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145834361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Zolpidem Withdrawal Delirium Developed as Severe Psychiatric and Physical Symptoms in a Patient With a History of Ovarian Cancer: A Case Report and Literature Review.","authors":"Junji Yamaguchi, Ryoichi Sadahiro, Saho Wada, Eri Nishikawa, Tatsuto Terada, Rika Nakahara, Hiromichi Matsuoka","doi":"10.1002/npr2.70090","DOIUrl":"10.1002/npr2.70090","url":null,"abstract":"<p><strong>Background: </strong>Zolpidem is a common medication for sleep disorders prescribed during or after cancer treatment. However, the possible risk of zolpidem withdrawal delirium does not seem to be well recognized by medical staff engaged in cancer treatment.</p><p><strong>Case presentation: </strong>A female in her 50s with a diagnosis of ovarian cancer underwent bilateral oophorectomy 6 years earlier. No recurrence was observed after treatment with anticancer drugs. She had been prescribed zolpidem (10 mg/day, oral) by her attending physician for approximately 5 years, although she often took it 2-3 times the dose when her insomnia was severe. At X years, she was hospitalized due to abdominal pain from infectious enteritis, and zolpidem was discontinued. On Day 3 of hospitalization, however, she became extremely confused and disoriented with psychomotor agitation, delusions, and myoclonus. Laboratory findings, brain magnetic resonance imaging (MRI), and spinal fluid examination denied encephalitis and encephalopathy. Finally, the patient was diagnosed with zolpidem withdrawal delirium, and lemborexant was effective for her sleep disorders. She was discharged on Day 22 with no aftereffects.</p><p><strong>Conclusions: </strong>Cancer patients might be relatively more prone to zolpidem withdrawal delirium because of the possible Blood-Brain Barrier dysfunction derived from anticancer drug treatment or cancer. Oncologists and liaison psychiatrists need to prevent and detect zolpidem withdrawal delirium because it may be difficult to manage withdrawal delirium with severe psychiatric symptoms in cancer hospitals with no dedicated psychiatric ward.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"46 1","pages":"e70090"},"PeriodicalIF":2.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12834464/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146053190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}